title: Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients.
abstract: OBJECTIVE
  In patients with end-stage renal disease (ESRD), the 25-hydroxyvitamin D3 (25(OH)D3) level is known to be lower compared to that of the normal population. In the present study, we evaluated the influences of dialysis methods on the serum 25(OH)D3 level in patients with ESRD who are treated with hemodialysis and peritoneal dialysis.
  
  
  METHODS
  Thirty-nine peritoneal dialysis (PD), 49 hemodialysis (HD) patients, and 33 healthy controls were included in the present study. The mean HD period was 30.38 +/- 21.81 months and the mean PD period was 26.35 +/- 24.04 months. Serum samples from the HD and PD patients and healthy controls were examined in terms of 25(OH)D3, intact parathyroid hormone (iPTH), and other biochemical laboratory tests. Additionally, the 25(OH)D3 level in the peritoneal fluid was analyzed in the PD group.
  
  
  RESULTS
  The mean 25(OH)D3 levels in the control, HD, and PD groups were 26.63 +/- 10.89, 21.65 +/- 12.38, and 13.46 +/- 9.41 nmol/l, respectively (P < 0.001). The mean peritoneal fluid 25(OH)D3 level was 28.53 +/- 7.66 nmol/l. Moreover, blood and PD fluid 25(OH)D3 levels were 34 compared in the PD group. The 25(OH)D3 level in dialysate was higher than that of serum in PD patients (P < 0.001).
  
  
  CONCLUSIONS
  The significantly lower blood levels of 25(OH)D3 in PD patients compared to those of HD patients were thought to be due to 25(OH)D3 loss via peritoneal fluid.
authors.affiliation: Nephrology Department, Eskisehir Osmangazi University Medical School, Büyükdere Mah. Mehmet Osman Sokak No:54/6, 26040, Merkez/Eskisehir, Turkey. garipsahin@superonline.com
authors.forename: Garip
authors.initials: G
authors.lastname: Sahin
authors.forename: Ismail
authors.initials: I
authors.lastname: Kirli
authors.forename: Basar
authors.initials: B
authors.lastname: Sirmagul
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Colak
authors.forename: Ahmet Ugur
authors.initials: AU
authors.lastname: Yalcin
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000419:Albuminuria / Q000175:diagnosis / Q000453:epidemiology; D000704:Analysis of Variance; D001202:Ascitic Fluid / Q000737:chemistry; D001774:Blood Chemical Analysis; D002112:Calcifediol / Q000172:deficiency*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D010530:Peritoneal Dialysis / Q000009:adverse effects* / Q000379:methods; D015995:Prevalence; D011336:Probability; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment; D017678:Sex Distribution; D014808:Vitamin D Deficiency / Q000175:diagnosis* / Q000453:epidemiology
chemical_list: D010281:Parathyroid Hormone; D002112:Calcifediol